ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
RASSF1A and its epigenetic dysregulation in genitourinary cancer: a current update.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RASSF1A is a tumor suppressor and is underexpressed in most cancers including genitourinary malignancies. RASSF1A is most frequently inactivated epigenetically following biallelic hypermethylation of its CpG islands involving DNA methyltransferases. Genitourinary malignancies result in profound morbidity and mortality especially in the old age people and hence discovery of novel therapeutic agents targeting the molecular aberrations are demanded for improved survival. In bladder cancer, RASSF1A downregulation is associated with modulation of key signaling process such as Hippo signaling pathway. Also, pharmacological activation of RASSF1A could augment the cytotoxicity induced by chemotherapeutic agents. Promoter methylation in RASSF1A in combination with other tumor suppressor genes (such as GSTP1 and MGMT) is also observed in the cancers of the male reproductive system and may aid in pathological classification as well as differentiation. In prostate cancer, RASSF1A promoter hypermethylation status could have key role in early diagnosis or modulating therapeutic response. Genitourinary malignancies having RASSF1A hypermethylation are also linked to poor patient prognosis. Evaluating RASSF1A methylation in a panel consisting of other tumor suppressor genes could plausibly improve the diagnostic accuracy in genitourinary cancers. Also, novel hypomethylating agents targeting the RASSF1A promoters could potentially enhance its reactivation in genitourinary cancers.
Indexed as
Identifiers
41144101What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.